Revitalizing ER+ Breast Cancer with Palazestrant and Ribociclib
Promising Advances in Breast Cancer Treatment Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a pioneering biopharmaceutical company specializing in breast cancer therapies, recently revealed compelling data from its Phase 1b/2 trial examining the effects of palazestrant combined with ribociclib in patients battling estrogen...
Continue Reading